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Abstract
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) acts through tumor vascular disruption and cytokine production
and is the first of its class to enter phase 3 trials. We characterized leukocytes and cytokines in murine Colon
38 tumors before and after DMXAA treatment. Tumor mass declined 50% 24 hours after DMXAA administration,
but the leukocyte count per gram of tumor increased threefold owing to a large influx of Ly6G+CD11b+F4/80− cells
with the morphology of neutrophils. However, B and T lymphocytes, natural killer cells, and macrophages in the
tumor all decreased in numbers. Seven chemokines were substantially induced in the tumor, spleen, and serum
4 hours after DMXAA administration. Using cultured spleen cell subpopulations, CD11b+ cells (largely monocytes
and macrophages) were shown to be the primary producers of tumor necrosis factor α, interleukin 6 (IL-6), and
macrophage inflammatory 1α (MIP-1α). CD49b+ natural killer cells produced IP-10, whereas CD45R+ B lymphocytes
produced regulated upon activation normal T cell express sequence. T lymphocytes were not major producers
of cytokines in the response to DMXAA. Murine peripheral blood leukocytes (PBLs) produced a similar panel of
cytokines in culture to that detected in mouse serum after DMXAA treatment. Cytokines in human PBL cultures
were subsequently measured with the aim of identifying potential serum markers of the human response to
DMXAA. IP-10 (P < .001), monocyte chemoattractant protein 1 (P < .001), and sCD40L (P < .01) were decreased,
whereas IL-8 (P < .001) and MIP-1α (P = .03) were increased in DMXAA-treated compared with untreated PBL
cultures from a group of 12 donors.
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Background
The leukocyte infiltrate, which comprises a major component of the
tumor stroma, is recognized as an important contributor to the cyto-
kine milieu that controls tumor growth. Current anticancer strategies
have seen a need to include approaches that target the tumor stroma,
and 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) is an
example of such an agent. DMXAA was developed at the Auckland
Cancer Society Research Centre [1] as a more potent derivative of
flavone acetic acid [2], and it is currently in phase 3 (Novartis,
ATTRACT-1 trial) clinical development for the treatment of non–
small cell lung carcinoma in combination with chemotherapy. A hall-
mark of the activity of these agents is the induction of hemorrhagic
necrosis in murine tumors, which resembles that induced with tumor
necrosis factor α (TNFα) [3]. Indeed, TNFα was produced after
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DMXAA treatment [4–6]. The antitumor activity in TNFα knock-
out and TNFα receptor 1 knockout mice was attenuated but not com-
pletely abolished, however, indicating that whereas TNFα plays a
role, other factors are also important [7]. Up-regulation of a number
of cytokine genes after DMXAA treatment has been demonstrated
[8–11]. Among these, interferons are abundantly produced [8,10]
and have been suggested to be responsible for dendritic cell activa-
tion and increases in tumor-specific CD8+ T cells that are seen in
DMXAA-treated mice [12]. We hypothesized that the induced cyto-
kine cascade will lead to an altered tumor microenvironment and
stromal cell infiltration. In this report, we examined changes in the
leukocyte infiltrate and cytokine concentrations in murine Colon 38
tumor before and after DMXAA treatment. Because cytokine induc-
tion seems an essential component of DMXAA’s activity in mice, we
also compared the in vitro response of cultured peripheral blood leu-
kocytes (PBLs) from mice and a group of 12 healthy donors to ex-
amine for interspecies differences and the variability between donors
in the response to DMXAA.
Materials and Methods
5,6-Dimethylxanthenone-4-Acetic Acid
DMXAAwas synthesized as the sodium salt at the Auckland Cancer
Society Research Centre [1] and dissolved fresh for each experiment
in saline. DMXAA was administered to mice by intraperitoneal in-
jection at 25 mg/kg. For in vitro experiments, DMXAA was dissolved
in culture medium, which was α-modified essential medium (Gibco
BRL, Grand Island, NY), supplemented with fetal calf serum (10%),
antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin), and
2-mercaptoethanol (50 μM).
Mice and Tumor Implants
C57Bl/6 mice were bred at the Vernon Jansen Unit, University of
Auckland, and were housed under conditions of constant tempera-
ture, lighting, and humidity. All experiments conformed to local in-
stitutional guidelines. Murine Colon 38 tumors are maintained by
serial transfer into syngeneic C57Bl/6 mice. Colon 38 tumors were
removed from donor mice and minced, and 1-mm2 fragments were
transferred into a subcutaneous pocket made in the left flank of anes-
thetized (100 mg/kg ketamine and 10 mg/kg xylazine) recipient
mice. Tumors were used for experiments when they were approxi-
mately 8 mm in diameter.
Characterization of Tumor-Infiltrating Leukocytes
Colon 38 tumors, excised at various times after DMXAA treat-
ment, were pressed through a stainless steel mesh into 20 ml of cul-
ture medium and aspirated to break up the large clumps. The
leukocytes were isolated by Ficoll-Paque PLUS (Pharmacia, Uppsala,
Sweden) density centrifugation. Cells in the leukocyte layer were in-
cubated with allophycocyanin-conjugated anti-CD45 antibodies to
label all leukocytes. Leukocyte subsets were identified by labeling
with two additional cell-type–specific antibodies; one of which would
be fluorescein isothiocyanate (FITC)–conjugated and the other
would be phycoerythrin (PE)-conjugated to allow triple staining of
each subset. The macrophage subpopulation of CD45+ leukocytes
was identified by colabeling with FITC–anti-CD11b and PE–anti–
F4/80 antibodies, that of natural killer (NK) cells was identified by
colabeling with FITC–anti-CD49b antibodies, that of B lympho-
cytes was identified by colabeling with FITC–anti-CD45R and
PE–anti-CD19 antibodies, and that of CD4+ and CD8+ T lympho-
cytes was identified by colabeling with PE–anti-CD3ɛ and FITC–
anti-CD4 or FITC–anti-CD8a antibodies, respectively. Antibodies
were purchased from Miltenyi Biotec (Bergish Gladbach, Germany)
and Serotec, Inc (Raleigh, NC). The cell populations were analyzed
using FACS Vantage cell sorter (BD Biosciences, NSW, Australia)
and CellQuest Pro software (BD Biosciences). The histologic diagno-
sis of each population was examined by hematoxylin and eosin stain-
ing of a cytospot of 2 × 105 cells of each fraction. Generally, groups
of 6 to 10 tumors were used for each labeling procedure.
Immunofluorescence Staining of Tumor Sections
Excised tumors in OCT (Tissue-Tek, Sakura Finetechnical, Tokyo,
Japan) were snap frozen in liquid nitrogen and stored at −80°C until
sectioning. Tumor sections of 7-μm thickness were mounted onto
glass slides and immunostained as previously described [13–15].
Primary rat antimouse antibodies used in these studies were as fol-
lows: FITC-labeled anti-CD11b (BD Pharmingen, San Diego, CA),
unconjugated anti–F4/80 (Serotec), and anti-Ly6G (BD Pharmingen).
Secondary antibodies used were Alexa Fluor 488–anti-FITC and Alexa
Fluor 555–antirat immunoglobulin (IgG) from Molecular Probes
(Eugene, OR). All antibodies were diluted with 1% goat serum in
Tris-buffered saline. When two primary antibodies raised in the same
species were applied to the same tumor section, they were applied
sequentially. Initially, sections were incubated with rat anti–F4/80
(10 μg/ml) or anti-Ly6G (10 μg/ml) and detected with antirat Alexa
Fluor 555. Tumor sections were then blocked with 5% rat serum to
bind any free sites on the antirat IgG secondary antibody. The sec-
tion was then probed with FITC-labeled anti-CD11b, which was
subsequently detected with an anti–FITC-Alexa Fluor 488 second-
ary antibody. Nuclei of cells were detected using 4′,6-diamidino-2-
phenylindole stain. After the final wash in Tris-buffered saline, sections
were mounted with Prolong Gold (Invitrogen, Christchurch, New
Zealand) and visualized sequentially using the 350 nm (blue), 470
to 490 nm (green), and 515 to 560 nm (red) excitation filters on a
Leica DMRE microscope and photographed using a Leica DC500
camera (Leica, Solms, Germany). Sequential images were processed
using Portia (CytoCode, Auckland, New Zealand; www.cytocode.
com). Negative control sections that were unstained or stained only
with secondary antibodies were used to determine the amount of
autofluorescence and to identify any potential nonspecific binding of
the secondary antibodies. These sections were also used to set the
input levels for each color such that the background autofluorescence
was reduced to zero, and this setting was applied to every image. Three
individual tumors per group were stained, and representative images
of each group are presented.
Preparation of Tumor, Spleen, and Serum Samples for
Cytokine Measurements
Mice with tumors, without treatment, or 2 to 6 hours after injec-
tion of DMXAA (25 mg/kg) were bled through the ocular sinus while
under isoflurane anesthesia. Tumors and spleens were excised after
cervical dislocation. Blood was allowed to clot overnight at 4°C and
was then centrifuged (2000g for 30 minutes at 4°C). The layer of se-
rum was transferred into fresh tubes and stored at −80°C until assay.
Tumors and spleens were weighed and homogenized in phosphate-
buffered saline with protease inhibitors (Sigma, St. Louis, MO). The
homogenates were centrifuged, and the supernatants were transferred
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to fresh tubes, which were recentrifuged before the supernatants
were transferred and stored at −80°C until assay. Groups of three mice
were used for each treatment group. Highest concentrations were
detected 4 hours after DMXAA injection. Only the data for the
4-hour time point have been presented and are consistent with un-
published data for cytokine induction by DMXAA in mice of different
strains and with different tumors models that have been carried out
for other studies.
Murine Splenocyte Cultures
Spleens from mice (three to six per experiment) were removed, the
cells were squeezed out into culture medium and aspirated to form a
single cell suspension, and red blood cells were removed by osmotic
lysis. Cells (3 × 106 cells per well) were cultured with DMXAA in
flat-bottomed 96-well plates in a total volume of 200 μl of culture
medium in a humidified incubator at 37°C with an atmosphere of
5% carbon dioxide in air. The supernatant from each well was re-
moved 4 hours after treatment and stored at −20°C until assay for
cytokines. Triplicate cultures per group were assayed.
MidiMACS separator cell isolation kits (Miltenyi Biotec) were used
following the manufacturer’s instructions to positively select for dif-
ferent splenocyte subpopulations for culture. Magnetically labeled
antibodies to CD11b, CD45R, and CD49b antigens, purchased from
Miltenyi Biotec, were used to isolate populations that were enriched
for macrophages, B lymphocytes, and NK cells, respectively, whereas
magnetically labeled anti-CD4 and anti-CD8a antibodies were used
to fractionate out the two subsets of T lymphocytes. The purity of
each fraction was determined by flow cytometry following labeling
of the positively selected subpopulation with FITC-conjugated anti-
bodies to the antigen used for selection. Only fractions that were
greater than 95% pure were used. The positively selected cells were
cultured as described above for the unfractionated splenocytes.
Cells from 10 spleens were pooled for the isolation of each cell type in
the first experiment. Generally, 10 spleens provided 6 × 108 nucleated
cells after osmotic lysis, fromwhich 3 × 108CD11b+, 6 to 9 × 107CD4+,
4 to 6 × 107 CD8+, and 1 to 2 × 106 CD49b+ cells could be ob-
tained. In a second experiment, CD11b and CD8 and/or CD 4 cells
were isolated from the one pool of 10 spleens, and CD49b and
CD45R and/or CD4 were isolated from a second pool of 10 spleens.
Peripheral Blood Leukocyte Cultures
Blood from halothane-anesthetized C57Bl/6 mice was collected
aseptically by cardiac puncture into heparinized tubes. Blood from
50 mice were pooled for the first experiment and from 30 mice
for the second experiment. Blood from healthy human donors were
obtained from NZ Blood Services. Blood from a total number of 12
donors were processed in batches of two to three per setup. Mono-
nuclear cells from murine or human blood were isolated using Ficoll-
Paque density centrifugation and were cultured in flat-bottomed
96-well plates (106 cells per well) with 10 or 300 μg/ml DMXAA
in a final volume of 200 μl of culture medium. Supernatants from
human and mouse PBL cultures were harvested after 16 and 4 hours,
respectively, and stored at −20°C until assay.
Multiplex Cytokine Assays
Multiplex cytokine kits; murine 22-plex and 32-plex; and human
7-plex, 30-plex, and 42-plex (Linco Research, St Charles, MO) were
used following the manufacturer’s instructions. Serum samples were
diluted 1:5, and tumor and spleen samples were diluted 1:10 with
matrix diluent supplied with the kits, and culture supernatants were
assayed undiluted. The concentration of each cytokine in the sam-
ples was read using the Luminex 100 instrument (Luminex Cor-
poration, Austin, TX). Each sample was assayed in duplicate, and
results were expressed as mean ± SEM from three mice per group
or triplicate cultures per experimental group. Data between untreated
and DMXAA-treated groups were compared using Student’s t tests
or one-way analysis of variance if multiple comparisons were made.
Paired t tests were carried out comparing cytokine concentrations
in treated and untreated cultures for all 12 donors (n = 36; trip-
licate cultures from 12 donors). Data were considered significant
when P ≤ .05.
Results
Effect of DMXAA on Leukocytes in the Colon 38 Tumor
The CD45+ leukocyte infiltrate in Colon 38 tumors was shown by
FACS analysis to comprise 43% CD3+CD8a+ cells (T lymphocytes
mainly), 20% CD3+CD4+ T cells, 12% CD19+CD45R+ B lympho-
cytes, 14% CD11b+F4/80− immature macrophages/monocytes, 11%
CD11b+F4/80+ mature macrophages, and 12% CD49b+ NK cells.
The weight and changes in the leukocyte content of groups of Colon
38 tumors before and 1, 3, 5, 7, and 10 days after a single injection
of DMXAA at its maximum tolerated dose of 25 mg/kg was moni-
tored (Figure 1). Tumor weights dropped nearly 70% during the first
3 days, then increased slightly during the next 4 days before a second
phase of tumor shrinkage was observed on day 7 (Figure 1A). The
number of CD45+ leukocytes per gram of tumor increased three-fold
during the first 24 hours after treatment when the tumor’s size was
decreasing. CD45+ leukocytes then dropped from 16 × 106 to a nadir
of 3 × 103 cells per gram tumor weight on day 3 (Figure 1B), before
increasing and stabilizing at 10 × 106 cells after 7 days. The increase
in leukocyte content during the first 24 hours was not due to an
influx of lymphoid cells. CD19+CD45R+ B lymphocytes, CD49b+
NK cells, and CD3+CD8a+ and CD3+CD4+ subsets (mainly T lympho-
cytes) all decreased in number during the first 3 days, then increased to
pretreatment levels after 7 days, and then stabilized (Figure 1C ).
CD11b+F4/80+ myeloid cells followed a similar pattern of change to
that of the lymphocytes (Figure 1D). CD11b+F4/80+ from untreated
tumors have the appearance of mature macrophages (Figure 1F). Strik-
ingly, the number of CD11b+F4/80− cells increased by 10-fold dur-
ing the first 24 hours (Figure 1D), and these cells from untreated
tumors have the appearance of immature monocytes (Figure 1E).
The influx of CD11b+F4/80− cells was confirmed by immunofluo-
rescence staining of Colon 38 cryosections with FITC–anti-CD11b
antibodies (green fluorescent) plus anti–F4/80 antibodies detected
with Alexa Fluor 555 (red fluorescent)–conjugated secondary anti-
bodies. In untreated tumors, a mixed population of CD11b+F4/80−
(green) and CD11b+F4/80+ (yellow) cells was seen in the tumor cap-
sule (Figure 2D). A large influx of CD11b+F4/80− (green) cells was seen
in the parenchyma of the tumor 24 hours after treatment (Figure 2E).
Tumors 7 days after treatment showed a mixture of CD11b+F4/80−
and CD11b+F4/80+ cells (Figure 2F ).
The CD11b+F4/80− cells from untreated tumors had the appear-
ance of monocytes (Figure 1E ), but neutrophils and a minor subset
of dendritic cells also share this phenotype. We therefore colabeled
sequential sections of tumors with the neutrophil-specific Ly6G
marker (Figure 2, G–I ), and hematoxylin and eosin–stained another
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set for histologic examinations (Figure 2, J–L). In untreated tumors,
most CD11b+ cells did not express Ly6G (green) and were seen
mainly in the capsule (Figure 2G ). One-day–treated tumors, con-
versely, show a large number of CD11b+Ly6G+ (yellow) cells in
the tumor parenchyma (Figure 2H ), and 7-day–treated tumors show
a mixture of CD11b+Ly6G+ and CD11b+Ly6G− cells (Figure 2I ).
The cells in the capsule of untreated tumors seem to be a mix of
monocytes and macrophages (Figure 2J ). Most cells seen in 1-day–
treated tumors, however, have the distinct twisted ring–shaped nuclei
of murine neutrophils (Figure 2K ), and these cells remain the dom-
inant cell-type seen in 7-day–treated tumors (Figure 2L).
Cytokines Induced with DMXAA in Tumor-Bearing Mice
We next investigated the production of chemokines that may have
influenced the influx of neutrophils into the tumor after treatment
with DMXAA. Highest concentrations of cytokines were detected
after 4 hours, and of the panel of 22 cytokines assayed, granulocyte–
colony-stimulating factor (G-CSF), interleukin 6 (IL-6), interferon-
inducible protein 10 (IP-10), keratinocyte-derived chemokine (KC),
monocyte chemoattractant protein 1 (MCP-1), macrophage inflam-
matory protein 1α (MIP-1α), regulated upon activation normal T-cell
express sequence (RANTES), and TNFα were highly induced in the
tumor (Figure 3A). These same eight cytokines were also detected
in spleen (Figure 3B) and in serum (Figure 3C). Low but statistically
significant increases in IL-10, IL-1α, and IL-1β were additionally
detected in the spleen. Although interferon γ (IFN-γ) levels increased
31-fold (250 pg/g in untreated compared with 7904 pg/g in DMXAA-
treated) in the spleen, it was not significant (P = .07). Cytokine con-
centrations in the serum were lower than those in the spleen, which
were lower than those in the tumor.
Cell Type Responsible for Producing the Cytokines
To investigate if different types were involved in producing the
various cytokines, splenocytes were fractionated, and the different
subsets were each cultured with DMXAA. The supernatants were
assayed for a panel of cytokines. Two different concentrations of
DMXAA were used: 10 μg/ml, which induces maximal production
Figure 1. Change in tumor weight (A) and number of CD45+ leukocytes (B), lymphoid populations (C), and myeloid cell populations (D)
isolated per gram of Colon 38 tumor after treatment with DMXAA at 25 mg/kg. Histologic diagnosis of hematoxylin and eosin–stained
CD11b+F4/80− (E) and CD11b+F4/80+ (F) cells extracted from untreated tumors (original magnification, ×400).
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TNFα, and 300 μg/ml, which induces maximal production of
IFN-γ in splenocyte cultures [16].
In cultures of unfractionated spleen cells, IL-6, IP-10, MIP-1α,
RANTES, and TNFα were shown to be induced with higher lev-
els obtained with 300 μg/ml DMXAA. IFN-γ was induced with
300 μg/ml but not with 10 μg/ml of DMXAA (Figure 4A). G-CSF,
KC, and MCP-1 produced in vivo in the spleen (Figure 3B) were not
detected in culture. IP-10 was the most abundant cytokine produced
in culture (Figure 4A) compared with IL-6, which is the most abun-
dant cytokine detected in vivo (Figure 3B).
Spleen cells were then fractionated using cell-type–specific anti-
bodies linked to magnetic beads. The purity of each positively se-
lected fraction was determined by examining an aliquot by FACS
analysis and used only if greater than 95% pure. In addition, the
histologic diagnosis of the cells in each fraction was examined. Of
note, and consistent with the lower side scatter profile obtained with
FACS of that fraction, the CD11b+ fraction was shown to be mainly
macrophages with less than 4% granulocytes. The various fractions
were each cultured at the same cell concentration with DMXAA at
10 and 300 μg/ml, and the supernatants were assayed for cytokines
compared with untreated cultures. The macrophage-enriched CD11b+
subset (Figure 4B) and the B-lymphocyte–enriched CD45R+ subset
(Figure 4C ) both responded better to DMXAA at 10 μg/ml. How-
ever, the CD49b+ NK cell population (Figure 4D) and the CD4+ and
CD8+ T-lymphocyte–enriched subsets (Figure 4, E and F ) produced
higher levels of cytokines at 300 μg/ml DMXAA. The CD11b+
macrophage-enriched fraction was the primary producer of TNFα
and IL-6 (Figure 4B). This fraction also produced high amounts of
MIP-1α to either concentration of DMXAA, as did the CD45R+ B-
lymphocyte fraction at 10 μg/ml (Figure 4C ), or the CD49b+ NK
Figure 2. Sequential sections of Colon 38 tumors from mice untreated (A, D, G, J) or 1 day (B, E, H, K) or 7 days (C, F, I, L) after treatment
with DMXAA (25 mg/kg) and immunostained with DAPI to locate the nuclei of cells in the tumor (t) and capsule (c) (A, B, C); immuno-
stained for CD11b+ (green), F4/80+ (red), and CD11b+ F4/80+ double positive (yellow/orange) cells (D, E, F); or immunostained for
CD11b+ (green), Ly6G+ (red), and CD11b+Ly6G+ double-positive (yellow/orange) cells (G, H, I). Images were acquired at original mag-
nifications of ×5 (C, F, I) and ×10 (A, B, D, E, G, H). Histologic diagnosis of cells in the capsular region of hematoxylin and eosin (H&E)–
stained sections (J, K, L) were acquired at an original magnification of ×100.
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cell–enriched fraction at 300 μg/ml (Figure 4D). The CD45R+ B lym-
phocytes were the main producers of IP-10, whereas the CD49b+
NK cells were the main producers of RANTES. The CD8a+ T-
lymphocyte–enriched fraction seem the best in producing IFN-γ
(Figure 4F ). Low but significant IFN-γ production was observed in
the CD49b+ and CD11b+ cell fractions (Figure 4, B and C). How-
ever, because a small proportion of NK cells also express the CD11b an-
tigen, we carried out an experiment to determine whether the IFN-γ
detected in the CD11b+ fraction was due to the NK cells. Firstly, we
depleted CD49b+ cells and then selected for CD11b+ cells in the
CD49b− fraction. The CD11b+ fraction that was devoid of CD49b+
NK cells was subsequently tested for IFN-γ production and was
shown not to produce IFN-γ in response to DMXAA at 300 μg/ml
(34 ± 16 pg/ml compared with 27 ± 14 pg/ml in untreated controls).
IFN-γ was produced, however, by the CD11b+ fraction that did not
have the CD49b NK cells removed (137 ± 20 pg/ml) and by the
CD49b+ fraction (150 ± 17 pg/ml). This result indicated that the
IFN-γ was most likely produced by CD11b+CD49b+ NK cells. Over-
all, the results in Figure 4 establish that multiple cell types contribute
to the cytokine response induced with DMXAA. Both the dose depen-
dency of each cell type to DMXAA and the panel of cytokines in-
duced differed.
Cytokine Response to DMXAA by Murine and Human PBLs
in Culture
The spectrum of cytokines induced in vitro by cultured murine
PBLs was next examined and compared with that detected in serum
of DMXAA-treated mice. The purpose for the comparison was to
establish if the in vitro response reflected the in vivo response.
DMXAA induced IP-10, MIP-1α, G-CSF, RANTES, IL-6, and
TNFα in murine PBL cultures in descending order of abundance
(Figure 5A). Although the relative abundances differed, the panel
Figure 3. Cytokine concentrations in Colon 38 tumors (A), spleen (B), and serum (C) from mice untreated (black bars) or 4 hours after
DMXAA (25 mg/kg) treatment (lined bars). #Above the minimum detection limit. *Significantly different from untreated controls (P< .05,
Student’s t test). +Above maximum detection limit.
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of cytokines detected in culture was identical to that detected in
serum (Figure 4A). The response of human PBLs in culture was
subsequently examined to provide insights into the human cytokine
response to DMXAA. Multiplex cytokine profiles for five individual
PBL donors ranging from the highest (Figure 5B) to the lowest
responder (Figure 5F ) in the cohort of 12 donors are shown in Fig-
ure 5, B–F. Unlike murine PBLs (Figure 5A), human PBLs in culture
constitutively produced IL-10, IL-8, IP-10, MCP-1, RANTES, and
sCD40L without treatment. The addition of DMXAA had no signif-
icant effect on RANTES concentrations but significantly decreased
levels of IP-10, MCP-1, and sCD40L (Table 1). Conversely, concen-
trations of IL-8 and MIP-1α were significantly increased (Table 1).
Tumor necrosis factor α and IL-6 were not constitutively produced,
and DMXAA did not induce their production in human PBL cul-
tures (Table 1), although the induction of these two cytokines pro-
vides a strong determinant of the cytokine response to DMXAA in
mice. The fold change in the concentrations of IP-10, sCD40L,
MCP-1, MIP-1α, IL-8, as well as that of TNFα and IL-6 for each
donor is presented in Figure 6. They show the trend of decreased
production of IP-10, MCP-1, and sCD40L in response to DMXAA
in most donors. Whereas TNFα, MIP-1α, IL-6, and IL-8 show a
trend of being increased with DMXAA treatment in some of the
donor PBL cultures, only the increases in IL-8 and MIP-1α con-
centrations reached statistical significance in the cohort (Table 1).
Discussion
The results here are the first to demonstrate a large influx of neu-
trophils into subcutaneously implanted Colon 38 tumors at a time
when T and B lymphocytes, NK cells, and macrophages were all de-
creasing in numbers after DMXAA treatment (Figure 1). Activated
neutrophils have been strongly implicated as mediators of endothelial
cell damage and killing during inflammation [17]. Our observations
here suggest that neutrophils may play a role in the antivascular ef-
fects of DMXAA. Endothelial cell apoptosis is seen in Colon 38 tu-
mors within 30 minutes of DMXAA administration [18], although
tumor vascular collapse is not measurable until 4 hours and is max-
imal after 24 hours [19,20]. The early influx of neutrophils into the
tumor could be a response to the endothelial cell damage. Increased
myeloperoxidase activity, indicative of increased neutrophil activity,
was also reported in murine sarcomas treated with another vascular
disrupting agent, combretastatin A-4 phosphate [21]. With DMXAA,
however, the production of chemokines that include MCP-1, MIP-
1α, KC, RANTES, and IP-10 in the tumor (Figure 3) may amplify
the initial influx, creating a more sustained antivascular action.
The results in Figure 3 confirm our previous studies [5–7] stating
that higher levels of TNFα are induced by DMXAA in the Colon 38
tumor than in the spleen or serum. In a rat model of chemically in-
duced primary mammary adenocarcinomas, DMXAA also induced a
significantly higher production of TNFα in the tumor than in the
serum [22]. In addition to its direct antivascular effects, TNFα has
been shown to promote adhesion and transmigration of neutrophils
into sites of inflammation by up-regulating the expression of cellular
adhesion molecules on endothelial cells [23]. Tumor necrosis factor α
may also activate neutrophils directly, as antibodies to TNFα ap-
plied to cultures of human neutrophils inhibited production of reac-
tive oxygen species [24]. The studies here indicate a potential role of
TNFα-activated neutrophils in the antivascular action of DMXAA in
rodent models.
Although TNFα has been the most studied, the multiplex assays
here show that TNFα concentrations are much lower than those of
IL-6, MCP-1, and MIP-1α that have been induced with DMXAA
(Figure 3). The role that each cytokine plays in the antitumor ac-
tion of DMXAA has not been fully investigated. It is likely that
they all play a part. Mice deficient in the expression or response to
a given cytokine all show restricted or reduced antitumor activity in
response to DMXAA. Colon 38 tumors in IFN-γ receptor knockout
mice regressed more slowly and required higher doses of DMXAA
Figure 4. Cytokine concentrations in supernatants from cultures of
unfractionated murine splenocytes (A), CD11b+ macrophage-
enriched (B), CD45R+ B-lymphocyte–enriched (C), CD49b+ NK
cell–enriched (D), CD4+ T-lymphocyte–enriched (E), and CD8a+
T-lymphocyte–enriched (F) spleen cell subsets; untreated (black
bars) or treated for 4 hours with DMXAA at 10 μg/ml (lined bars)
or 300 μg/ml (hatched bars). #Above minimum detection limit. *Sta-
tistically different from untreated controls (P< .05, one-way analysis
of variance). +Above maximum detection limit.
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Figure 5. Cytokine concentrations in culture supernatants from murine PBLs (A), untreated (black bars) or treated for 4 hours with 10 μg/ml
DMXAA, and PBLs from a human donor (B, C, D, E, F) untreated (black bars) or 16 hours after treatment with DMXAA at 300 μg/ml (hatched
bars). #Above minimum detection limit. *Statistically different from untreated controls (P < .05, Student’s t test).
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than in wild-type mice [25]. The antitumor activity in TNFα knock-
out and TNFα receptor 1 knockout mice was also attenuated, requiring
higher doses of DMXAA to achieve a similar degree of hemor-
rhagic necrosis and cures in Colon 38 tumors compared with that
in wild-type mice [7]. Growth inhibition against Lewis lung car-
cinomas was not observed in IFN-β knockout mice at a dose of
DMXAA that produced a modest growth delay in wild-type mice
[26]. IFN-β is abundantly produced by murine macrophages in re-
sponse to DMXAA [8,27], but this cytokine is unfortunately not
available in the multiplex cytokine assays for inclusion into these
studies. Up-regulation of IFN-β messenger RNA expression was not
detected in Colon 38 tumors after DMXAA treatment, however [10].
The central role of B lymphocytes in the host cell infiltrate in
chronic inflammation and carcinogenesis has lately been recognized
[28]. We show here that B lymphocytes constitute approximately
12% of the leukocyte infiltrate in Colon 38 tumors. B lymphocytes
were shown to be the primary producers of IP-10 in the response to
DMXAA (Figure 4). Along with macrophages, B lymphocytes also
produced high amounts of MIP-1α, one of the more abundantly in-
duced chemokines after DMXAA treatment in mice. Macrophages
were the primary source of TNFα and IL-6 (Figure 4). Natural killer
cells were the main producers of RANTES, whereas both NK cells
and CD8+ T lymphocytes produced IFN-γ in response to DMXAA
(Figure 4). T lymphocytes on the whole did not seem to be major
contributors to the cytokine response, consistent with the limited de-
tection of T-cell cytokines such as IL-2 in the response to DMXAA.
B lymphocytes and macrophages required lower concentrations of
DMXAA than NK and T lymphocytes for maximal cytokine pro-
duction (Figure 3). These results establish that different cell types
exhibit different dose dependencies for DMXAA. They also explain
our earlier observations that maximal production of TNFα (by macro-
phages) was obtained at 10 μg/ml, whereas maximal IFN-γ pro-
duction (from NK and T cells) was obtained using 300 μg/ml of
DMXAA [16]. The differential dose requirements of the various
cell types could be due to the differential expression of the yet un-
identified receptor for DMXAA. Cytokine induction by DMXAA
seems not to involve Toll-like receptors and is MyD88-independent
[12,27,29]. Tumor necrosis factor α and IFN-γ production and nu-
clear factor κB (NF-κB) activation were concomitantly blocked using
NF-κB inhibitors salicylate and parthenolide in DMXAA-treated mu-
rine splenocyte cultures, implicating the involvement of signaling
through NF-κB [9]. Conversely, up-regulation of IFN-β gene tran-
scription by DMXAA in primary murine macrophages was critically
dependent on the TANK-binding kinase 1–interferon regulatory
factor 3 signaling axis and did not seem to involve NF-κB [27]. Cur-
rent studies in our laboratory defining the molecular mode of action
of DMXAA indicate that multiple targets and signaling pathways
may be involved.
The cytokines induced with DMXAA in murine PBL cultures was
similar to that obtained in the serum of mice after DMXAA treat-
ment (Figures 3 and 4). This observation suggested that the in vitro
activity can be indicative of the in vivo response. With this perspec-
tive, the response of cultured human PBLs was examined in an effort
to obtain the determinants of the cytokine response to DMXAA in
humans. The studies have clearly demonstrated that DMXAA affects
cytokine production in human PBLs. They also demonstrate that the
pattern of regulation by DMXAA on human and murine PBLs may
be considerably different. One major difference is that human PBLs
produced high quantities of a number of cytokines in culture with-
out treatment (Figure 5 and Table 1), whereas constitutive cytokine
production by murine PBLs without treatment was minimal (Fig-
ure 5A). DMXAA was shown to downregulate the production of some
of the constitutively produced cytokines, notably IP-10, MCP-1, and
sCD40L. At the same time, other cytokines, which include IL-8 and
MIP-1α, were upregulated by DMXAA. The inhibitory action of
DMXAA is not apparent in studies with murine PBLs because they
are not constitutively producing cytokines in culture without an
added stimulus. Whether DMXAA would inhibit cytokine produc-
tion in murine leukocytes if they were constitutively activated is not
known. The simultaneous yet seemingly opposing regulatory actions
of DMXAA on human PBLs could be explained on the basis that dif-
ferent cell types producing the various cytokines are differentially reg-
ulated by DMXAA. Differential responses to DMXAA by different
subsets of murine splenocytes were established in the studies shown
Table 1. Cytokine Concentrations in Untreated and DMXAA-Treated Cultures of Human PBLs.
Donor Cytokine Concentration (pg/ml)
IP-10 MCP-1 sCD40L TNFα MIP-1α IL-6 IL-8
Untreated Treated Untreated Treated Untreated Treated Untreated Treated Untreated Treated Untreated Treated Untreated Treated
1 481 ± 58 8 ± 5* 45 ± 10 4 ± 0* 295 ± 80 71 ± 36 4 ± 0 7 ± 4 4 ± 1 17 ± 10 6 ± 3 12 ± 8 180 ± 62 2327 ± 892
2 2352 ± 105 252 ± 39* 175 ± 5 45 ± 8* 294 ± 64 111 ± 40 7 ± 0 14 ± 3* 14 ± 1 105 ± 27* 6 ± 0 85 ± 2* 326 ± 13 2763 ± 127*
3 536 ± 49 206 ± 58* 100 ± 12 28 ± 3* 1539 ± 173 529 ± 31* 5 ± 0 37 ± 17 12 ± 2 239 ± 103 4 ± 1 39 ± 19 205 ± 21 3961 ± 218*
4 429 ± 102 159 ± 27 245 ± 37 136 ± 66 133 ± 11 27 ± 3* 5 ± 0 26 ± 22 7 ± 2 188 ± 176 14 ± 1 489 ± 467 328 ± 22 2156 ± 374*
5 322 ± 97 55 ± 19* 150 ± 24 37 ± 7* 156 ± 7 30 ± 1* <LLD <LLD 5 ± 1 18 ± 3* 9 ± 1 52 ± 6* 373 ± 19 2301 ± 113*
6 174 ± 7 77 ± 2* 79 ± 43 14 ± 1 151 ± 16 25 ± 0* 7 ± 2 5 ± 0 11 ± 8 17 ± 1 17 ± 2 40 ± 3* 357 ± 82 1859 ± 63*
7 74 ± 30 82 ± 8 267 ± 44 45 ± 6* 32 ± 12 13 ± 5 5 ± 0 4 ± 1 18 ± 1 18 ± 3 13 ± 1 27 ± 3* 362 ± 50 1751 ± 116*
8 1235 ± 197 314 ± 27* 99 ± 6 17 ± 5* 1047 ± 111 518 ± 38* 4 ± 0 <LLD 13 ± 2 12 ± 1 7 ± 0 19 ± 1* 153 ± 6 174 ± 18
9 812 ± 134 355 ± 48* 350 ± 51 86 ± 23* 178 ± 17 55 ± 19* 4 ± 0 <LLD 6 ± 0 4 ± 1 <LLD 6 ± 2 351 ± 55 1115 ± 125*
10 128 ± 39 220 ± 41 679 ± 167 316 ± 66 70 ± 10 20 ± 3* 4 ± 1 <LLD 4 ± 1 5 ± 1 3 ± 2 10 ± 4 464 ± 81 1529 ± 62*
11 550 ± 43 49 ± 13* 349 ± 36 33 ± 11* 15 ± 8 35 ± 2* 9 ± 0 4 ± 1* 12 ± 1 6 ± 1* 9 ± 1 30 ± 4* 340 ± 25 542 ± 17*
12 382 ± 14 262 ± 30* 177 ± 49 58 ± 2 142 ± 22 94 ± 17 4 ± 0 <LLD 5 ± 2 5 ± 2 4 ± 0 <LLD 222 ± 49 160 ± 20
Mean ± SEM† 623 ± 104 170 ± 20 226 ± 31 68 ± 15 346 ± 76 127 ± 31 5 ± 0 9 ± 3 9 ± 1 53 ± 19 8 ± 1 68 ± 39 305 ± 19 1720 ± 194
P <.001 <.001 <.010 =.106 =.030 =.132 <.001
PBLs were cultured for 16 hours with DMXAA (300 μg/ml) or without treatment. Cytokine concentrations in supernatants were determined using multiplex cytokine assays. Means ± SEM of triplicate
treated and untreated cultures for each cytokine and for each donor were compared using Student’s t tests.
LLD indicates lower limits of detection.
*P < .05.
†Mean ± SEM of all untreated or treated cultures (n = 36, triplicate cultures/donor × 12 donors). P values shown reflect a comparison of treated and untreated cultures using paired t tests.
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in Figure 3, and studies with fractionated subpopulations of human
PBLs are planned.
Another notable difference between the murine and human re-
sponse to DMXAA is the modest or insignificant effects on IL-6
and TNFα in human PBLs. The low induction of TNFα seen in this
study is compatible with that in previous studies of TNFα induction
by DMXAA in human PBLs [30,31] and with data from the clinical
trials [32–34]. On the basis of studies on rodents [5–7,22], TNFα
only was evaluated as a surrogate marker of activity in the phase 1
and 2 trials of DMXAA [30–32]. The results here show significant
increases in IL-8 concentrations in our cohort of 12 donors, and IL-8
may be a more dependable marker than TNFα. However, because
of the complexity of the cytokine response and the differential re-
sponses of the various cell types in the blood, we suggest that mon-
itoring the effects on a panel of cytokines would be more appropriate.
The panel that we have derived from the analysis of the data from the
large multiplex screens includes IP-10, MCP-1, sCD40L, IL-8, and
MIP-1. Tumor necrosis factor α and IL-6 were also included for
comparisons with murine studies and with earlier studies in hu-
mans. Presentation of the fold change in the concentration of this
panel of cytokines provided a relatively uncomplicated way to com-
pare or rank the responsiveness of the donors. The studies with our
Figure 6. Fold change in cytokine concentrations in supernatants from untreated and DMXAA-treated (16 hours, 300 μg/ml) PBL cultures
from individual donors. NC indicates no change.
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small cohort of 12 donors suggest considerable variability between
individuals in the response of the PBLs in culture to DMXAA (Fig-
ure 6). Determination of whether the responsiveness of their PBLs in
culture correlates with a patient’s responsiveness to DMXAA treat-
ment is clearly outside the scope of our studies. The phase 3 trials
of DMXAA, however, would provide an excellent opportunity for
such determinations to be made.
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